Last €2.97 EUR
Change Today -0.019 / -0.64%
Volume 50.3K
As of 1:15 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

aap implantate (AAQ) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/3/14 - €3.65
52 Week Low
08/2/13 - €1.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AAP IMPLANTATE (AAQ)

Related News

No related news articles were found.

aap implantate (AAQ) Related Businessweek News

No Related Businessweek News Found

aap implantate (AAQ) Details

aap Implantate AG, a medical device company, researches, develops, manufactures, and sells implants, medical instruments, bone cements, and replacement materials for use in orthopedic procedures in Germany and internationally. It provides LOQTEQ, an anatomical angular stable plating system for compressing fractures with angular stable locking screws; and fragment set comprising T, L, quarter tubular, and reconstruction plates, as well as cortical and cancellous screws. It also offers cannulated screws for the treatment of hand and foot fracture; AcroPlate, which is used for the treatment of AC joint injuries; and autodynamic plating systems for secure fracture stabilization. In addition, the company provides a range of bone cements and accessories for application in arthroplasty, vertebroplasty, and kyphoplasty; and collagen fleeces for ambulant and stationary tissue care. Further, it offers bone substitutes that includes Artosal, a synthetic osteoconductive bone substitute; Cerabone, a ceramic bone substitute; OsteoCem, a calcium phosphate cement; Osnatal, a human bone allograft; and PerOssal, a synthetic bone substitute and carrier material. The company sells its products through its direct sales force, and distribution partners, as well as through license agreements with OEM partners. aap Implantate AG is headquartered in Berlin, Germany.

199 Employees
Last Reported Date: 05/16/14

aap implantate (AAQ) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €381.0K
Chief Finance Officer and Member of the Manag...
Total Annual Compensation: €260.0K
Compensation as of Fiscal Year 2013.

aap implantate (AAQ) Key Developments

AAP Implantate AG Reports Sales Results for the Second Quarter and Six Months of 2014

AAP Implantate AG reported sales results for the second quarter and six months of 2014. For the quarter, the company reported sales from continued operations of EUR 8.0 million against EUR 6.6 million a year ago. For the six months, the company reported sales from continued operations of EUR 14.2 million against EUR 12.6 million a year ago. Total sales were EUR 15.2 million against EUR 19.6 million a year ago.

AAP Implantate AG Reports Consolidated Earnings Results for the First Quarter of 2014; Provides Earnings Guidance for the Second Quarter and Full Year of 2014

AAP Implantate AG reported consolidated earnings results for the first quarter of 2014. For the quarter, sales were EUR 7.1 million against EUR 10.4 million a year ago. EBITDA was EUR 0.1 million against EUR 3.1 million a year ago. LBIT was EUR 0.4 million against EBIT of EUR 2.3 million a year ago. For the second quarter of 2014, the company expects sales to be between EUR 7.6 million and EUR 8.2 million. The EBITDA forecast amounts between EUR 1.0 million and EUR 1.5 million. The management board is reaffirming the sales and EBITDA outlook for the full year of 2014. Sales to be EUR 35 million and an EBITDA of between EUR 5 million and EUR 6 million.

aap Implantate AG Announces Management Changes

aap Implantate AG announced that its Supervisory Board named Bruke Seyoum Alemu, Chief Operating Officer of aap Implantate AG since 2008, as the company's new chairman of the Management Board and Chief Executive Officer, effective as of June 1, 2014. The Supervisory Board and the Management Board have agreed to reduce the size of aap's Management Board from three to two members. Current CEO Biense Visser and the Supervisory Board have agreed to terminate Mr. Visser's Management Board contract prematurely as of May 31, 2014. To maintain continuity, Mr. Visser is prepared to serve on aap Implantate AG's Supervisory Board provided that the necessary legal requirements are fulfilled. The company assumes that its majority shareholders will support Mr. Visser's move to the Supervisory Board and nominate him accordingly on the occasion of the upcoming annual shareholders meeting. Starting from the effective date and as members of the Management Board of aap Implantate AG, Mr. Alemu will be in charge of Product Development, Sales and Marketing, Supply Chain and Business Development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AAQ:GR €2.97 EUR -0.019

AAQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AAQ.
View Industry Companies

Industry Analysis


Industry Average

Valuation AAQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AAP IMPLANTATE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at